ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis (Accreta, Increta, Percreta).
Overview
Placenta previa totalis (accreta, increta, percreta); ADAMTS and proteoglycans and the oxidant / antioxidant enzyme levels.
Full Title of Study: “ADAMTS, Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis(Accreta, Increta, Percreta)”
Study Type
- Study Type: Observational [Patient Registry]
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 2014
Detailed Description
Placenta previa totalis (accreta, increta, percreta) of pregnant women in the maternal serum, fetal membranes (placenta) and hysterectomy of women with myometrial strips measured the ADAMTS and proteoglycans expression levels, and the oxidant / antioxidant enzyme levels.
Arms, Groups and Cohorts
- Placenta previa
- first; maternal serum, fetal membranes (placenta) and maternal myometrial samples will be investigated for ADAMTS, Proteoglycans and oxidative/antioxidative enzyme status levels in patients with placental invasion anomalies Placenta Previa totalis by ELISA, western blot, immunohystochemistry and PCR (polymerase chain reaction).
Clinical Trial Outcome Measures
Primary Measures
- ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of maternal serum in patients with the diagnosis of Placenta Previa (Accreta, increta, percreta)
- Time Frame: Up to 6 months
Secondary Measures
- ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of myometrial samples in patients with the diagnosis of Placenta Previa (Accreta, increta, percreta)
- Time Frame: Up to 6 months
- ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Fetal Membranes in patients with the diagnosis of Placenta Previa (Accreta, increta, percreta)
- Time Frame: Up to 6 months
- placenta previa totalis in the development, progression and in exacerbating; ADAMTS and proteoglycans, to determine the relationship of changes in expression.
- Time Frame: Up to 2 years
Participating in This Clinical Trial
Inclusion Criteria
- pregnant women diagnosed with placenta previa by obstetric ultrasound and doppler Exclusion Criteria:
- Pregnant women with comorbid diseases other than previa totalis .
Gender Eligibility: Female
Minimum Age: 25 Years
Maximum Age: 40 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Zekai Tahir Burak Women’s Health Research and Education Hospital
- Provider of Information About this Clinical Study
- Principal Investigator: sibel özler, ADAMTS, Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis(Accreta, Increta, Percreta) – Zekai Tahir Burak Women’s Health Research and Education Hospital
- Overall Official(s)
- ahmet nuri danısman, md, Study Director, zekai tahir burak women’s health education and research hospital
- Overall Contact(s)
- sibel özler, md, 05457970257, sibelozler@gmail.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.